FRANKLIN, Mass., May 24 /PRNewswire/ -- Arthrosurface, Inc. (www.arthrosurface.com), the developer of inlay joint resurfacing systems, announced the achievement of a significant clinical milestone. Over 20,000 patients, typically middle aged, have been treated with the various Arthrosurface cartilage resurfacing systems, with the early patients now 6 years post surgery.
“Back in 2003, there was no accepted surgical ‘next step’ for those patients that had exhausted conservative & biological therapies such as drug injections & microfracture. With the passing of the 20,000 patient milestone and with more than 98% of the implants still in place, we have achieved our initial goal of providing a less invasive option that would allow patients to go back to an active lifestyle while delaying the need for a joint replacement,” commented Steven Ek, COO.
“For very advanced disease in the older aged patient, joint replacement still provides a good option. However, the baby boomer population has been the silent sufferer. They have joint pain, limited mobility and all the signs of early articular cartilage damage. In my opinion, a well accepted treatment for early disease in the boomer population does not exist. Having the Arthrosurface technology as an interim treatment has provided a great new option for these patients,” remarked Anthony Schepsis, MD, Professor of Orthopaedic Surgery at Boston University. “For me and thousands of other surgeons, this system has been a very effective solution for those patients that have failed early treatments and yet are too young for a total joint replacement. The Arthrosurface system has filled this gap in my sports medicine practice.”
The Arthrosurface inlay resurfacing technology was developed to treat the young and active patient typically referred to as the baby boomer. The company’s technology uses a family of implants with different shapes and sizes to effectively recreate the patient’s joint geometry with an intraoperative 3D mapping instrument set. Arthrosurface has been a leader in introducing anatomic inlay resurfacing in the knee, shoulder and toe. The company’s focus remains dedicated to early joint resurfacing for the boomer population. The company’s systems are indicated and FDA cleared for use in the knee, shoulder, hip and toe.
SOURCE Arthrosurface, Inc.
